CGRP
A 37-amino-acid sensory neuropeptide that is one of the body's most potent vasodilators and the validated pharmacological target behind modern anti-migraine therapy.
CGRP (calcitonin gene-related peptide) is a 37-amino-acid endogenous neuropeptide produced by alternative splicing of the calcitonin gene and expressed predominantly in sensory neurons of the trigeminal system and peripheral vasculature. It acts as a potent vasodilator and pain neuromodulator central to migraine pathophysiology, signaling through the CLR/RAMP1 receptor complex. CGRP itself is not a compounded therapeutic; the FDA-approved interventions are the monoclonal antibodies and small-molecule antagonists that block its pathway, while exogenous CGRP peptide is used strictly as a research tool in vasodilation and pain-signaling studies.
Class
Endogenous 37-amino-acid sensory neuropeptide
Routes
Subcutaneous, Intravenous
Category
Immune & Mitochondrial
Researched benefits
What it's studied for
Potent vasodilation
CGRP is one of the most powerful endogenous vasodilators known, relaxing vascular smooth muscle via a cAMP/PKA and nitric oxide pathway after binding the CLR/RAMP1 receptor complex. This action underlies its role in regulating blood flow and cerebral vascular tone.
Pain and nociceptive modulation
Released from trigeminal sensory neurons, CGRP amplifies nociceptive signaling and is elevated in plasma during migraine attacks. Blocking this signaling is the validated mechanism behind modern preventive and acute migraine drugs.
Bone repair and osseointegration
CGRP secretion promotes bone cell differentiation and integration; preclinical work shows CGRP release around implants supports osseointegration and restoration of sensory feedback (osseoperception).
Wound healing
As a neuropeptide contributing to neurovascular and angiogenic responses, CGRP participates in coordinated tissue-repair signaling, an area explored in diabetic wound-repair models.
Mechanism
How it works
CGRP is generated by tissue-specific alternative splicing of the calcitonin gene and is expressed predominantly in sensory neurons of the trigeminal system and along peripheral vasculature. It exists as two closely related isoforms, alpha-CGRP and beta-CGRP.
The peptide exerts its effects by binding the CLR/RAMP1 receptor complex, triggering a cAMP/PKA cascade and nitric-oxide-mediated relaxation of vascular smooth muscle. This produces the potent vasodilation for which CGRP is best known and shapes cerebral and peripheral blood flow.
In the trigeminal system, activation during migraine releases CGRP at elevated plasma concentrations, amplifying nociceptive (pain) signaling. Because this release is central to migraine pathophysiology, blockade of the CGRP pathway — with receptor or ligand monoclonal antibodies and small-molecule gepant antagonists — has become the primary validated target for preventive and acute migraine therapy.
Beyond pain and vasotone, CGRP contributes to peripheral anti-inflammatory signaling, bone healing and osseointegration, and neurovascular/angiogenic responses involved in wound repair, which are the focus of ongoing preclinical research.
Evidence
Research & clinical studies (10)
A Controlled Trial of Erenumab for Episodic Migraine (STRIVE)
Monthly subcutaneous erenumab at 70 mg and 140 mg reduced mean monthly migraine days by 3.2 and 3.7 versus 1.8 for placebo, with 43-50% of participants achieving at least a 50% reduction, establishing CGRP receptor blockade as an effective preventive approach.
PMID 29171821Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful (LIBERTY)
Monthly erenumab 140 mg achieved a 50% or greater migraine-day reduction in 30% of treatment-refractory patients versus 14% for placebo, demonstrating CGRP receptor blockade efficacy in difficult-to-treat migraine.
PMID 30360965Three-year real-world effectiveness, treatment persistence, and planned discontinuation of anti-CGRP monoclonal antibodies for migraine prevention: a single-center cohort from Japan
Anti-CGRP monoclonal antibodies sustained effectiveness over three years with 56% of patients continuing treatment and durable reductions in migraine days and disability, with discontinuations largely reflecting achieved treatment goals rather than adverse events.
PMID 42211313A Self-Powered, Cold-Responsive Pyroelectric Biointerface Restores Implant Osseoperception and Osseointegration
A pyroelectric titanium implant coating converted cold stimuli into electrical signals that increased CGRP secretion, promoting bone cell differentiation and restoring both sensory feedback and bone integration in a rat model without external power.
PMID 42216421Astrocyte-Targeted Biomarkers for Calcitonin Gene-Related Peptide-Related Neurovascular Disorders: Insights from Calcium and Metabolic Profiling
Profiling of calcium and metabolic signatures identified astrocyte-targeted biomarkers relevant to CGRP-related neurovascular disorders.
PMID 42368049Luteolin reduces sciatic nerve damage and modulates TRPV1 and TRPM2 expression in diabetic rats
Luteolin reduced sciatic nerve damage and modulated TRPV1 and TRPM2 channel expression in a diabetic rat model relevant to CGRP-associated nociceptive signaling.
PMID 42364240CGRP-targeted migraine treatment and early pathophysiology in experimental subarachnoid hemorrhage
CGRP blockade before experimental subarachnoid hemorrhage improved early cerebral blood flow and motor performance in rats, and early hemorrhage reduced CGRP release from the dura mater while leaving trigeminal ganglion release unchanged.
PMID 42215868Population Pharmacokinetics and Exposure-Response Analyses for Ubrogepant Efficacy and Safety in the Acute Treatment of Migraine: Analysis of Phase 1-3 Studies
A population PK model for the CGRP antagonist ubrogepant showed significant exposure-response relationships for pain relief and pain freedom, with benefit observed even when dosed during the migraine prodrome.
PMID 42212509Functional role of Nav1.8 channels in action potentials of mouse CGRP-lineage dorsal root ganglion neurons
Nav1.8 sodium channels carried the majority of sodium current during action potentials in CGRP-lineage nociceptors and were the dominant driver of repetitive firing, setting action potential threshold alongside faster-activating Nav1.7 channels.
PMID 42218117A Hydrogen Sulfide-Releasing Dynamic Hydrogel Modulates Coordinated Neurovascular, Immune, and Angiogenic Responses for Scar-Suppressed Diabetic Wound Repair
A hydrogen-sulfide-releasing hydrogel coordinated neurovascular, immune, and angiogenic responses to achieve scar-suppressed diabetic wound repair in models involving CGRP-associated signaling.
PMID 42363818Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Cardiovascular conditions
- Pregnancy or nursing
CGRP carries a moderate risk profile in research contexts. Because it is a potent vasodilator, cardiovascular conditions are a key consideration, and use during pregnancy or nursing is not advised. Review contraindications and consult a qualified healthcare professional before any decision.
FAQ
CGRP — common questions
What is CGRP?
CGRP (calcitonin gene-related peptide) is a 37-amino-acid endogenous neuropeptide produced by alternative splicing of the calcitonin gene, expressed predominantly in sensory neurons of the trigeminal system and peripheral vasculature. It functions as a potent vasodilator and pain neuromodulator central to migraine pathophysiology, signaling through the CLR/RAMP1 receptor complex.
What is CGRP primarily studied for?
Its main research areas are vasodilation, pain modulation, wound healing, and bone repair.
Why is CGRP important in migraine?
During migraine attacks, trigeminal activation releases CGRP at elevated plasma concentrations, amplifying pain signaling. Blocking this pathway is the primary validated pharmacological target for modern preventive and acute migraine therapy, supporting FDA approval of anti-CGRP monoclonal antibodies such as erenumab, fremanezumab, and galcanezumab.
Is CGRP something a provider compounds or administers?
No. CGRP itself is an endogenous neuropeptide and not a compounded or administered therapeutic. The FDA-approved interventions are monoclonal antibodies and small-molecule receptor antagonists (gepants) available by prescription, while exogenous CGRP peptide is used only as a research tool compound in vasodilation and pain-signaling studies.
What does the research show about CGRP-pathway therapy?
In the LIBERTY phase 3b trial, monthly erenumab 140 mg (a CGRP receptor antibody) achieved a 50% or greater migraine-day reduction in 30% of treatment-refractory patients versus 14% for placebo, and the STRIVE trial showed similar preventive efficacy in episodic migraine.
What are the safety considerations for CGRP?
Reported contraindications and considerations include cardiovascular conditions and pregnancy or nursing. It has a moderate risk profile; consult a qualified healthcare professional before use.
